Bengaluru's LiteFold launched Rosalind, an AI 'co-scientist' platform for biotech research. It targets a key bottleneck: computational biologists spend significant time building software before solving biological problems. The platform claims to accelerate drug development by running hundreds of hypotheses in parallel, cutting down discovery time.
How We Got Here
Founder Anindyadeep Sannigrahi began developing the platform in 2025 at Bengaluru's Lossfunk, a year after computational protein design won a Nobel Prize. He initially aimed to build an IDE for computational biologists, before co-founding LiteFold with American ML engineer Cory Kornowicz.
The Numbers
- The five-member startup operates out of Bengaluru and Delaware, US.
- Co-founder Cory Kornowicz joined after seeing Sannigrahi's early posts on X.
- Its AI co-scientist, Rosalind, integrates several stages from AI workflows to legal processes on a single platform, excluding physical wet lab testing.
- LiteFold's long-term vision extends beyond therapeutic design to broader biological engineering applications.
What Happens Next
🇮🇳 Why This Matters for India
For India's deep-tech founders and computational biologists in Bengaluru's growing biotech hub, LiteFold signals a domestic shift towards AI-native platforms over traditional tool-building.
The Take
If LiteFold successfully operationalizes 'Rosalind' at scale, it won't just speed up R&D; it will lower the barrier for individual scientists and smaller labs to pursue complex biological hypotheses. Expect a talent shift as more ML engineers pivot into biotech within the next 24 months.
Source:
YourStory ↗